Category: Combined Treatment

Probability of survival

Clinical study for Advanced Pancreas Cancer treated by Oncothermia

Clinical study for Advanced Pancreas Cancer treated by Oncothermia Probability of survival Contact Us Summary Presented are clinical studies of pancreas cancer (PCA), an aggressive and common tumour. The studies took place in two centers and both made the treatments by oncothermia combined with the conventional therapies. The final results show an exceptional survival benefit […]

PS Values

WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer

WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer PS Values Contact Us Summary Wilms’ tumor 1 (WT1) is a tumor-linked antigen highly expressed in cancer. We examined the safety of WT1-peptide pulsed dendritic cell (WT1-DC) vaccine in combination with chemotherapy in patients with surgically resected pancreatic cancer. immunotherapy has been put forward […]

Response rate with DCTs

Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer

Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer Response rate with DCTs Contact Us Summary This study analyzes the combination of dendritic cell (DC) with autologous cytokine-induced killer (CIK) immunotherapy in setting of high-dose […]

Cum Survival

Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer

Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer Contact Us Summary In this study it was hypothesized that combination of dendritic cell (DC) with autologous cytokine-induced killer (CIK) immunotherapy in setting of high-dose chemotherapy […]

Overall Survival

Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine‐induced killer cell therapy in hepatobiliary and pancreatic cancer

Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine‐induced killer cell therapy in hepatobiliary and pancreatic cancer Contact Us Summary The goal of this study was to discover the therapeutic effects of adoptive immunotherapy following dendritic cell (DC) vaccine and cytokine-induced killer (CIK) cell therapy and evaluate its cytotoxicity, survival benefits and quality of […]

AML Cancer Cells

Effects of Dendritic Cell-activated and Cytokine-induced Killer Cell Therapy on 22 Children with Acute Myeloid Leukemia after Chemotherapy

Effects of Dendritic Cell-activated and Cytokine-induced Killer Cell Therapy on 22 Children with Acute Myeloid Leukemia after Chemotherapy Contact Us Summary This study investigated the efficiency of dendritic cell-activated and cytokine-induced killer cell (DC-CIK) therapy on children with acute myeloid leukemia (AML) after chemotherapy was investigated. The results conclude, MRD in children with AML can […]

Percentage of Progression vs Survival

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients Contact Us Summary This study describes the immune response elicited by two vaccine approaches using the wild-type (wt) p53 vaccine. The founding suggest that using either vaccination approach […]

After 2 cycles of infusion

The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study

The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study Contact Us Summary In this study, we evaluated the efficacy and safety of a combination treatment of axitinib and dendritic cells-co-cultured cytokine-induced killer cells in patients with advanced renal […]

MRI Scan

Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study

Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study Contact Us Summary DC loaded with proteins derived from autologous tumour homogenate is used for the treatment of patients with relapsed malignant glioma. As a result the approach may prolong survival of patients with malignant brain tumours without compromising […]

Plasma Samples

Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer

Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer Contact Us Summary The study investigates a phase Ib/II trial evaluating low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory (R/R) esophageal, gastric or colorectal cancers. The safety and efficacy of decitabine-primed re-sensitization to chemoimmunotherapy is promising. […]